Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Esketamine/Alcohol Use Disorder (AUD)

Esketamine for Alcohol Use Disorder (AUD)

3 papers and 1 clinical trial exploring esketamine as a treatment for alcohol use disorder (aud).

Compounddissociative

Esketamine

Esketamine (Spravato) is the S-enantiomer of ketamine, approved as an intranasal treatment for treatment-resistant depression and MDD with acute suicidal ideation. It is administered under clinical supervision with post-dose monitoring and has reached over $1.6 billion in annual sales.

Full Esketamine profile
IndicationOver 100 million cases worldwide, making AUD the most common substance use disorder.

Alcohol Use Disorder (AUD)

Alcohol Use Disorder (AUD) is a prevalent condition characterised by an inability to control alcohol consumption despite adverse consequences. Emerging research indicates that psychedelics may offer promising therapeutic avenues for treating AUD, with various compounds showing potential in clinical trials.

Full Alcohol Use Disorder (AUD) profile

Academic Research

3 papers
Open Accessindividual

Esketamine combined with a mindfulness-based intervention for individuals with alcohol problems

In a double-blind, randomised pilot study of 28 people with alcohol problems, sublingual esketamine (115.1 mg) combined with two weeks of daily mindfulness-based intervention increased psychological engagement with the practice and produced transient reductions in alcohol craving versus placebo. Esketamine also elicited greater mystical and dissociative experiences, suggesting these altered states may underlie enhanced engagement and potential therapeutic benefit.

Published
June 11, 2024
Journal
Journal of Psychopharmacology
Authors
Gent, E. M., Bryan, J. W., Cleary, M. A., Clarke, T. I., Holmwood, H. D., Nassereddine, R. O., Salway, C., Depla, S., Statton, S., Krecké, J., Morgan, C. J.
Paywallindividual

Barriers to Esketamine Nasal Spray Treatment Among Adults With Treatment-Resistant Depression

This retrospective observational cohort study (n=966 esketamine initiators, n=39,219 controls) examines factors influencing esketamine initiation and continuation for treatment-resistant depression (TRD). Initiators resided closer to treatment centres, with initiation rates decreasing significantly with distance. Factors associated with increased initiation included posttraumatic stress disorder, suicidal ideation, and male sex, while Medicaid, substance use disorder, older age, and greater distance were associated with lower initiation rates.

Published
May 6, 2024
Journal
Journal of Clinical Psychiatry
Authors
Joshi, K., Liberman, J. N., Parab, P., Darer, J. D., Harding, L.
Paywallmeta

Ensuring the affordable becomes accessible-lessons from ketamine, a new treatment for severe depression

The paper uses ketamine as a case study to show that market and regulatory failures allowed a costly patented intranasal s‑ketamine (Spravato®) to be commercialised while inexpensive generic racemic ketamine—apparently at least as effective—remained under‑evaluated and largely inaccessible. The authors recommend systemic reforms, including commercial incentives, public and public–private funding, reduced regulatory barriers and coordinated international funding, to ensure affordable off‑patent treatments become accessible.

Published
October 13, 2023
Journal
Australian and new-zealand Journal of Psychiatry
Authors
Rodgers, A., Bahceci, D., Davey, C. G., Chatterton, M. L., Glozier, N., Hopwood, M., Loo, C.

Clinical Trials

1 trial
CompletedPhase II

Esketamine (AWKN002) Combined with Mindfulness-Based Intervention for Alcohol Use Disorder: A Double-Blind Pilot RCT (Gent 2024, University of Exeter)

This unregistered trial (n=28) was a double-blind, placebo-controlled pilot RCT of esketamine combined with mindfulness-based intervention for alcohol use disorder in adults, which found that esketamine enhanced psychological engagement and transiently reduced alcohol cravings.

Started
January 1, 2021
Type
interventional
Blinding
double
Randomized
Yes
Registry ID
GENT-2024-JPP-ESKETAMINE-AUD-EXETER

Explore further

Search all Esketamine papers Search all Alcohol Use Disorder (AUD) trials Full Esketamine profile Full Alcohol Use Disorder (AUD) profile